It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

HER2-Positive Locally Advanced/Metastatic Breast Cancer Treatment Study

Clinical Trial Title: 
A randomized, multicenter, open label study of MM-302 plus trastuzumab vs. chemotherapy of physician's choice plus trastuzumab in anthracycline naive patients with locally advanced/metastatic HER2-positive breast cancer.
Clinical Trial Protocol ID: 
14050808
Clinical Trial Investigator Name: 
Melody A. Cobleigh, MD
Clinical Trial Protocol Description: 

The main purpose of this study is to see whether MM-302 plus an anticancer drug called trastuzumab is more effective than other anticancer drugs (gemcitabine, capecitabine, or vinorelbine). The study will also see whether subjects taking MM-302 plus trastuzumab live longer, have fewer symptoms related to their cancer, experience a better quality of life, and have fewer side effects than subjects receiving other anticancer drugs.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have histologically or cytologically confirmed invasive cancer of the breast.
  • Have documented locally advanced/ metastatic disease which is not amenable to resection with curative intent.
  • Have been previously treated with trastuzumab in any setting.
  • Have progressed on or be intolerant to both pertuzumab and ado-trastuzumab in the locally advanced or metastatic setting.

You will be excluded from the study if any of the following criteria apply to you:

  • Have previously been treated with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other anthracycline derivative.
  • Have central nervous system (CNS) metastases, unless you have been treated and are stable without symptoms for 4 weeks after completion of treatment and must be off steroids for at least 4 weeks prior to enrollment.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Breast Cancer
Contact Phone: 
(312) 942-3732
Contact Name: 
Chrystie Paul, RN, BSN